Stocks and Investing Stocks and Investing
Fri, November 29, 2024
[ 04:00 AM ] - United States, Thomas Matters
Investors Looking for Stability Tap South Africa in Trump Era
[ 03:30 AM ] - United States, Thomas Matters
Scotia Global Asset Management announces fee reductions and year-end distribution estimates
[ 02:31 AM ] - United States, Thomas Matters
Active momentum funds gather steam as large fund houses enter the fray
[ 02:31 AM ] - United States, Thomas Matters
5 Mistakes to Avoid While Christmas Shopping at Costco This Year
[ 01:31 AM ] - United States, Thomas Matters
The Best Warren Buffett Stock to Buy With $500 Right Now
[ 12:31 AM ] - United States, Thomas Matters
7.7 million Australians are investing in ASX shares. Why aren't you?
[ 12:31 AM ] - United States, Thomas Matters
The Globe and Mail's 2024 Robo-Adviser Guide
[ 12:30 AM ] - United States, Thomas Matters
Bullish on Tesla, Apple, Nvidia? 4 ways to invest in international stocks
Thu, November 28, 2024
[ 11:58 PM ] - United States, Thomas Matters
Money blog: 'Commuter town' named least affordable place to buy house in UK
[ 11:58 PM ] - United States, Thomas Matters
Chart of the week: Morningstar's 10 year return projections for markets
[ 11:58 PM ] - United States, Thomas Matters
Demand for active ETFs is growing among Canadian investors
[ 11:57 PM ] - United States, Thomas Matters
Could SoundHound AI Be the Next Palantir?
[ 11:57 PM ] - United States, Thomas Matters
7 ways to invest like you're rich, even if you're not yet
[ 03:34 PM ] - United States, Thomas Matters
3 Millionaire-Maker Technology Stocks to Consider
[ 03:34 PM ] - United States, Thomas Matters
Here Are My 2 Favourite TSX Stocks to Buy for December
[ 12:20 PM ] - United States, Thomas Matters
Crocs' Discounted P/E Valuation: Is it a Value Bet for Investors?
[ 12:00 PM ] - United States, Thomas Matters
Down More Than 20% From Its High, Is Now the Time to Buy Eli Lilly Stock?
[ 11:41 AM ] - United States, Thomas Matters
Is Nvidia Stock on Sale?
[ 11:21 AM ] - United States, Thomas Matters
Crypto Is Soaring After Trump's Election: 6 Reasons You Still Shouldn't Go All In
[ 11:21 AM ] - United States, Thomas Matters
Low costs, potential gains increasingly drawing investors to active ETFs
[ 11:21 AM ] - United States, Thomas Matters
Palantir Vs. Super Micro Computer: A Tale Of Two Camps
[ 11:21 AM ] - United States, Thomas Matters
Invest Smart: The Best Funds to Grow Your Money Today
[ 11:21 AM ] - United States, Thomas Matters
Investing in the Stock Market with Just ?10: Is It Possible?
[ 11:21 AM ] - United States, Thomas Matters
The top ten stocks investors hold in their Isas - .. how much tax-free investing could have saved them
[ 11:21 AM ] - United States, Thomas Matters
SPGP: Balancing Growth And Value, But Falling Short
[ 09:21 AM ] - United States, Thomas Matters
Money blog: Anger as Manchester United raise ticket prices to cover operational costs
[ 09:21 AM ] - United States, Thomas Matters
Stocks slip the day before Thanksgiving as Nvidia, Dell decline
[ 09:21 AM ] - United States, Thomas Matters
These are the top 3 risks to the US stock market rally, according to Deutsche Bank
[ 09:20 AM ] - United States, Thomas Matters
The5%ers Review 2024: Everything You Need to Know Before Signing Up
[ 09:01 AM ] - United States, Thomas Matters
Is Pfizer Stock in Trouble?

Is Pfizer Stock in Trouble?


Published on 2024-11-28 09:01:00 - Thomas Matters, WOPRAI
  Print publication without navigation

  • One stock that just can't seem to catch a break of late is Pfizer (NYSE: PFE). Given how well Pfizer has performed in recent years due to its COVID-19 vaccine and pill (its revenue topped $100 billion in 2022),

The article from AOL discusses the challenges faced by Pfizer Inc. as its stock has experienced a significant decline, dropping by 30% in the past year. This downturn is attributed to several factors including the waning demand for its COVID-19 vaccine and treatment, Comirnaty and Paxlovid, as the global health crisis transitions into an endemic phase. Additionally, Pfizer is dealing with patent expirations, increased competition from generic drugs, and a broader market shift away from pharmaceutical stocks. The company's efforts to diversify its portfolio through acquisitions and new product development are highlighted, but these initiatives have not yet offset the revenue loss from its blockbuster drugs. The article also touches on the broader implications for investors, suggesting that while Pfizer faces immediate headwinds, its long-term strategy might still hold promise if new products gain traction.

Read the Full AOL Article at [ https://www.aol.com/pfizer-stock-trouble-111700534.html ]

Contributing Sources